Discontinuation of high- versus middle-efficacy disease-modifying treatment in middle-aged patients with multiple sclerosis
Résumé
Meeting Abstract EP1163
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis
Amsterdam, NETHERLANDS
OCT 26-28, 2022